Private equity firms including EQT, Advent, and KKR are circling PolyPeptide Group, as the Swiss drug manufacturer launches a strategic review that could lead to a potential transaction.

The company confirmed it is assessing strategic options in coordination with its majority shareholder, as part of its ongoing efforts to enhance long-term value creation. However, there is no certainty that this will result in a deal.

PolyPeptide’s response comes after Bloomberg had reported earlier that EQT, Advent and KKR were interested in a takeover. The group acknowledged the speculations, but declined to provide further comment on the media reports.

PolyPeptide operates as a contract development and manufacturing organisation specialising in peptide-based active pharmaceutical ingredients, with a global footprint spanning Europe, the US, and India.

The company is positioned to benefit from rising demand for peptide-based therapies, including treatments targeting obesity and diabetes, and is currently executing a turnaround strategy aimed at scaling production capacity and improving operational performance.

Investor sentiment has already responded to the developments, with PolyPeptide’s shares rising more than 13% following reports of takeover interest, marking the stock’s strongest performance in over two years.

If you think we missed any important news, please do not hesitate to contact us at [email protected].

Can`t stop reading? Read more.